p53 is a large, complex, and difficult to manufacture protein with low commercial yields. Pharmaceutical companies have been forced to conduct drug screens using p53 fragments, hyper-stable mutants, and computer modeling, until now.
Finger Lakes Bio's patent-pending biological production technology enables scalable manufacturing and purification of hard or impossible to express recombinant proteins, including p53.
Yields in excess of 3mg/L were achieved in E.coli, easily scalable up to 100 mg batches. Current commercial availability allows only microgram quantities with unknown bioactivity at a cost of over $20k/mg.